The Royal Marsden
The Royal Marsden was the world's first hospital dedicated to cancer (1851) and is paired with the Institute of Cancer Research.
With the ICR, discovered abiraterone and olaparib's clinical path (PARP inhibitors in BRCA, de Bono/Tutt); leads prostate (STAMPEDE) and breast trials; MR-linac pioneer.
- Prostate cancer (abiraterone, PARP)
- MR-linac
- Breast cancer
Led OlympiA, the trial that showed a year of olaparib after surgery improves survival in BRCA-mutated breast cancer.
Gastrointestinal oncologist who led landmark trials of perioperative chemotherapy in gastric and oesophageal cancer.
Melanoma and kidney cancer trialist who co-led CheckMate 067, the trial with 10-year immunotherapy survival data.
Johann de Bono led the trials that brought abiraterone and olaparib to prostate cancer patients.
Kevin Harrington is a head and neck oncologist and oncolytic virus pioneer who led the OPTiM trial of T-VEC.
Nicholas James is chief investigator of STAMPEDE, the platform trial that reshaped treatment of advanced prostate cancer.
Breast cancer researcher who turned ctDNA into a tool for choosing treatment, leading SERENA-6 and CAPItello-291.
Uwe Oelfke is the radiotherapy physicist behind the Marsden's pioneering MR-linac programme.
Patients with head and neck squamous cell cancer that has recurred or spread should be treated first with pembrolizumab: alone if their tumour is strongly PD-L1 positive and they can wait for a slower response, or with chemotherapy if the tumour is bulky or PD-L1 low. Cetuximab-based chemotherapy is no longer the default. Long-term follow-up shows a small but real group of patients alive at four to five years, which was almost unheard of before.
Men diagnosed with prostate cancer that has already spread, or that is locally advanced and high risk, should start abiraterone (or another androgen-receptor pathway inhibitor) at the same time as testosterone suppression rather than waiting for resistance. This roughly halves the risk of death over several years. The same platform later showed that docetaxel chemotherapy and, in high-volume metastatic disease, triple therapy also help, and that abiraterone benefits men with high-risk disease treated with radiotherapy.
Pages like this
not linked directly; found by shared links- IdeaCore-funded radiotherapy trials infrastructure with central quality assurance
Shares Uwe Oelfke, A statutory minimum share of public trial money for surgery and radiotherapy, MR-guided adaptive radiotherapy, The Institute of Cancer Research.
- InstitutionGuy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre
Shares Andrew Tutt, The Institute of Cancer Research, PARP inhibitors, Olaparib.
- InstitutionThe Christie NHS Foundation Trust
Shares Evening and weekend trial clinics for working-age patients, A statutory minimum share of public trial money for surgery and radiotherapy, Mesothelioma, Fragmented care and guideline gaps.
- IdeaTrial-in-a-box: a preconfigured protocol kit any hospital can open for a rare cancer
Shares Mesothelioma, Biliary tract cancer (cholangiocarcinoma), Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).
- IdeaOne global rare cancer network with n-of-1 and Bayesian trial frameworks
Shares Mesothelioma, Biliary tract cancer (cholangiocarcinoma), Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).
- IdeaFunded research pathways for surgeon-scientists and radiation oncologist-scientists
Shares Kevin Harrington, A permanently funded international network for randomised cancer surgery trials, Surgery and radiotherapy cure most, get least.
- TrialPROfound
Shares Johann de Bono, Olaparib, Prostate cancer.
- IdeaAn open model bank for the rare tumours nobody has models for
Shares Mesothelioma, Biliary tract cancer (cholangiocarcinoma), Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).